Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01511913 · ClinicalTrials.gov registry record
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 1,411
- Enrollment target
NCT01511913: Completed study, sponsored by Bristol-Myers Squibb.
NCT01511913 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,411 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01511913 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 1,411 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the safety of Ipilimumab and patterns of use in the treatment of unresectable or metastatic melanoma in the post-approval setting
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,411 participants |
| Start Date | 2012-06-03 |
| Est. Completion | 2019-12-12 |
What the finished NCT01511913 record still lists
NCT01511913 is an observational study that tracks outcomes without assigning an intervention. Its 1,411 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT01511913 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01511913 about?
NCT01511913 is a clinical study titled "A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma". The purpose of this study is to examine the safety of Ipilimumab and patterns of use in the treatment of unresectable or metastatic melanoma in the post-approval setting
What is the current status of trial NCT01511913?
This trial is currently completed. The enrollment target is 1,411 participants. The study started on 2012-06-03. Estimated completion is 2019-12-12.
Who is sponsoring clinical trial NCT01511913?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05890404 · 1,410 participants · NA
SGM Evidenced-Based Mental Healthcare Implementation
- NCT07042451 · 1,410 participants · NA
An Evaluation of the Pink Cloud Application in Post- Treatment Substance Use Disorder Support
- NCT07222566 · 1,410 participants · Phase 3
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- NCT05992935 · 1,405 participants · Phase 1
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI